standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Intensive conventional chemotherapy (ACVBP regimen) compared with

[1]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[2]  P. Gaulard,et al.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .

[4]  B. Coiffier,et al.  Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Severson,et al.  Non-Hodgkin's Lymphoma: An analysis of the Metropolitan Detroit SEER Database , 2000, Cancer investigation.

[6]  K. Maclennan,et al.  A Randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma , 2000 .

[7]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Kaasa,et al.  CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[11]  B. Coiffier,et al.  Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Leukemia & lymphoma.

[12]  J. Matthews,et al.  Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. López-Guillermo,et al.  CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial , 1996, European journal of haematology.

[14]  S. Treon,et al.  Concepts in use of high-dose methotrexate therapy. , 1996, Clinical chemistry.

[15]  B. Coiffier,et al.  Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W Hop,et al.  Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Iannitto,et al.  Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. , 1995, Leukemia & lymphoma.

[18]  M. Gospodarowicz,et al.  Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[19]  C Sebban,et al.  Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[21]  L. Gordon,et al.  Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[22]  T. Fears,et al.  Non-Hodgkin's lymphoma time trends: United States and international data. , 1992, Cancer research.

[23]  C. Gisselbrecht,et al.  Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Hryniuk,et al.  The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Jaffe,et al.  Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Bloomfield,et al.  A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non‐Hodgkin's lymphomas cancer and leukemia group B study 7851 , 1990, Cancer.

[27]  B. Coiffier,et al.  LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Berger,et al.  Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival. , 1987, Blood.

[29]  J. D. H. Freeman.  Applied categorical data analysis , 1987 .

[30]  G. Pinkus,et al.  Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.

[31]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[32]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[33]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .